Intelligence Feed event · Options · 2026-10-12

    GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food Spend

    Question

    GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food Spend

    Direct answer

    Data indicates that 11% of adult Americans now use GLP-1 receptor agonist therapies for diabetes and weight management. The rapid uptake has translated into elevated top-line growth for pharmaceutical leaders Eli Lilly and Novo Nordisk. Conversely, reduced overall caloric intake and behavioral changes among users are directly dampening grocery expenditure on processed snacks and carbonated beverages, creating sustained volume headwinds for names like PepsiCo, Mondelez, and Hershey.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food Spend”, revision 1, evidence through 2026-10-12. https://marketontology.com/market-events/2026-10-12/glp-1-adoption-reaches-11-of-us-adults-pressuring-packaged-food-spend-ba0846

    OPTIONS
    GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food Spend
    Data indicates that 11% of adult Americans now use GLP-1 receptor agonist therapies for diabetes and weight management. The rapid uptake has translated into elevated top-line growth for pharmaceutical leaders Eli Lilly and Novo Nordisk. Conversely, reduced overall caloric intake and behavioral changes among users are directly dampening grocery expenditure on processed snacks and carbonated beverages, creating sustained volume headwinds for names like PepsiCo, Mondelez, and Hershey.
    LLYPEPMDLZ
    Impact
    71
    OCT 12
    SIG
    84%
    LLYPEPMDLZ
    GLP-1 Adoption Reaches 11% of US Adults, Pressuring Packaged Food Spend
    Data indicates that 11% of adult Americans now use GLP-1 receptor agonist therapies for diabetes and weight management. The rapid uptake has translated into elevated top-line growth for pharmaceutical leaders Eli Lilly and Novo Nordisk. Conversely, reduced overall caloric intake and behavioral changes among users are directly dampening grocery expenditure on processed snacks and carbonated beverages, creating sustained volume headwinds for names like PepsiCo, Mondelez, and Hershey.
    → Caloric reduction among 11% of adult consumers decreases volume demand for high-sugar snacks, compressing operating margins across packaged food equities.
    Impact
    Data indicates that 11% of adult Americans now use GLP-1 receptor agonist therapies for diabetes and weight management. The rapid uptake has translated into elevated top-line growth for pharmaceutical leaders Eli Lilly and Novo Nordisk. Conversely, reduced overall caloric intake and behavioral changes among users are directly dampening grocery expenditure on processed snacks and carbonated beverages, creating sustained volume headwinds for names like PepsiCo, Mondelez, and Hershey.
    Affected
    LLYPEPMDLZ
    Transmission
    Caloric reduction among 11% of adult consumers decreases volume demand for high-sugar snacks, compressing operating margins across packaged food equities.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYprescription volume revenue accelerationUp1-3m11% US adult adoption rate supporting sustained Zepbound sales momentum.
    PEPpackaged snack volume contractionDown1-3mGLP-1 users significantly reduce processed snack and high-calorie beverage consumption.
    MDLZpackaged confectionery volume contractionDown1-3mConsumer grocery spend declines in confectionery categories among GLP-1 users.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    LLYUp1188.72 2026-10-07PendingPendingPending
    PEPDowndisagreed126.68 2026-10-12+0.49%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month